Cargando…

Targeting TRAIL Death Receptors in Triple-Negative Breast Cancers: Challenges and Strategies for Cancer Therapy

The tumor necrosis factor (TNF) superfamily member TNF-related apoptosis-inducing ligand (TRAIL) induces apoptosis in cancer cells via death receptor (DR) activation with little toxicity to normal cells or tissues. The selectivity for activating apoptosis in cancer cells confers an ideal therapeutic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kundu, Manjari, Greer, Yoshimi Endo, Dine, Jennifer L., Lipkowitz, Stanley
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9739296/ https://www.ncbi.nlm.nih.gov/pubmed/36496977 http://dx.doi.org/10.3390/cells11233717

Ejemplares similares

MEDI3039, a novel highly potent tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 2 agonist, causes regression of orthotopic tumors and inhibits outgrowth of metastatic triple-negative breast cancer
por: Greer, Yoshimi Endo, et al.
Publicado: (2019)

Targeting Mitochondria with ClpP Agonists as a Novel Therapeutic Opportunity in Breast Cancer
por: Wedam, Rohan, et al.
Publicado: (2023)

TIC10/ONC201: a bend in the road to clinical development
por: Greer, Yoshimi Endo, et al.
Publicado: (2015)

Novel Apoptosis-Inducing Agents for the Treatment of Cancer, a New Arsenal in the Toolbox
por: Lim, Bora, et al.
Publicado: (2019)

CIB1 depletion with docetaxel or TRAIL enhances triple-negative breast cancer cell death
por: Chung, Alexander H., et al.
Publicado: (2019)

Identification of novel molecular regulators of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in breast cancer cells by RNAi screening
por: Garimella, Sireesha V, et al.
Publicado: (2014)

The Combination of TRAIL Treatment and Cancer Cell Selective Expression of TRAIL-Death Receptor DR4 Induces Cell Death in TRAIL-Resistant Cancer Cells
por: Choi, Eunah, et al.
Publicado: (2006)

Multi-omics analyses reveal ClpP activators disrupt essential mitochondrial pathways in triple-negative breast cancer
por: Fennell, Emily M. J., et al.
Publicado: (2023)

Regulation of Cancer Metastasis by TRAIL/Death Receptor Signaling
por: Oh, You-Take, et al.
Publicado: (2021)

Mitochondrial Matrix Protease ClpP Agonists Inhibit Cancer Stem Cell Function in Breast Cancer Cells by Disrupting Mitochondrial Homeostasis
por: Greer, Yoshimi Endo, et al.
Publicado: (2022)

Synergistic antitumor effects of circularly permuted TRAIL with doxorubicin in triple-negative breast cancer: Circularly permuted TRAIL with Dox in TNBC
por: Liu, Jia, et al.
Publicado: (2023)

Targeting Death Receptor TRAIL-R2 by Chalcones for TRAIL-Induced Apoptosis in Cancer Cells
por: Szliszka, Ewelina, et al.
Publicado: (2012)

Glutamine metabolism regulates FLIP expression and sensitivity to TRAIL in triple-negative breast cancer cells
por: Mauro-Lizcano, Marta, et al.
Publicado: (2018)

Triple negative breast cancer: the kiss of death
por: Jitariu, Adriana-Andreea, et al.
Publicado: (2017)

TRAIL Induces Nuclear Translocation and Chromatin Localization of TRAIL Death Receptors
por: Mert, Ufuk, et al.
Publicado: (2019)

Therapeutic targeting of TRAIL death receptors
por: Di Cristofano, Francesca, et al.
Publicado: (2023)

Therapeutic Strategies for Metastatic Triple-Negative Breast Cancers: From Negative to Positive
por: Nandini, Dey, et al.
Publicado: (2021)

Tristetraprolin Posttranscriptionally Downregulates TRAIL Death Receptors
por: Lee, Won Hyeok, et al.
Publicado: (2020)

Minimal dosing of leukocyte targeting TRAIL decreases triple-negative breast cancer metastasis following tumor resection
por: Jyotsana, Nidhi, et al.
Publicado: (2019)

Triple negative breast cancer: A continuing challenge
por: Gupta, Sudeep
Publicado: (2013)

Triple-negative breast cancer: treatment challenges and solutions
por: Collignon, Joëlle, et al.
Publicado: (2016)

Targeted Therapeutic Strategies for Triple-Negative Breast Cancer
por: Li, Ying, et al.
Publicado: (2021)

Phase I/Ib study of olaparib and carboplatin in women with triple negative breast cancer
por: Lee, Jung-Min, et al.
Publicado: (2017)

Untangling Triple-Negative Breast Cancer Molecular Peculiarity and Chemo-Resistance: Trailing Towards Marker-Based Targeted Therapies
por: Kanwal, Bushra
Publicado: (2021)

TRAIL and curcumin codelivery nanoparticles enhance TRAIL-induced apoptosis through upregulation of death receptors
por: Yang, Xi, et al.
Publicado: (2017)

Apoptotic Resistance of Metastatic Tumor Cells in Triple Negative Breast Cancer: Roles of Death Receptor-5
por: Kamalabadi-Farahani, Mohammad, et al.
Publicado: (2019)

Triple Negative Breast Cancer: Nanosolutions for a Big Challenge
por: Mendes, Tânia Filipa S., et al.
Publicado: (2015)

Metastatic and triple-negative breast cancer: challenges and treatment options
por: Al-Mahmood, Sumayah, et al.
Publicado: (2018)

Current Progresses and Challenges of Immunotherapy in Triple-Negative Breast Cancer
por: Mediratta, Karan, et al.
Publicado: (2020)

Overexpression of Programmed Death-Ligand 1 Receptor mRNA as an Independent Negative Prognostic Factor for Triple Negative Breast Cancer
por: Purwanto, Ibnu, et al.
Publicado: (2020)

Triple-negative breast cancer: current treatment strategies and factors of negative prognosis
por: Baranova, Anna, et al.
Publicado: (2022)

Death Receptor 5 Displayed on Extracellular Vesicles Decreases TRAIL Sensitivity of Colon Cancer Cells
por: Setroikromo, Rita, et al.
Publicado: (2020)

Update on triple-negative breast cancer: prognosis and management strategies
por: Brouckaert, Olivier, et al.
Publicado: (2012)

Novel therapeutic strategies for patients with triple-negative breast cancer
por: Zhang, Jun-Fei, et al.
Publicado: (2016)

Novel therapeutic strategies in the treatment of triple-negative breast cancer
por: Oualla, Karima, et al.
Publicado: (2017)

Novel strategies to target chemoresistant triple-negative breast cancer
por: Venkatesh, Jaganathan, et al.
Publicado: (2020)

Emerging treatment strategies for metastatic triple-negative breast cancer
por: Huppert, Laura A., et al.
Publicado: (2022)

The nature of triple-negative breast cancer classification and antitumoral strategies
por: Kim, Songmi, et al.
Publicado: (2020)

Recent advances in therapeutic strategies for triple-negative breast cancer
por: Li, Yun, et al.
Publicado: (2022)

Recent advances in targeted strategies for triple-negative breast cancer
por: Zhu, Shuangli, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_efhg5qh53066hkphrei22u9pm0